Market Overview

Bank Of America Hikes Pfizer Price Target, Estimates Citing Orphan Drug Catalysts

Share:
Bank Of America Hikes Pfizer Price Target, Estimates Citing Orphan Drug Catalysts

Large-cap pharma stocks have seen a mixed performance in year to date, and among this group, Pfizer Inc. (NYSE: PFE) is poised to benefit from some key second-half catalysts, according to an analyst at Bank of America Merrill Lynch.

The Analyst

Jason Gerberry reiterated a Buy rating on Pfizer and raised the price target from $45 to $48, attributing the revision to higher estimates, with double-digit EPS growth in the 2020-2023 timeframe and pipeline optionality.

The Thesis

Pfizer may soon transform from being a fringe player in the orphan drugs to a mainstream company, given three upcoming catalysts in the segment, Gerberry said in a note.

The analyst sees the Vyndaqel launch in cardiomyopathy as a catalyst, citing bullish feedback of KOL physicians on immediate conversion of existing U.S. patients. Long-term orphan drug launch analysis suggests scope for market expansion and in turn upside to BofA's above-consensus forecast, the analyst added. Gerberry estimates peak sales of $2 billion for the drug.

Gerberry also sees upside optionality in DMD gene therapy candidate ‘9926 for which a Phase 1 data readout is scheduled for mid-2019. If the data is positive, the analyst said, Pfizer can directly launch a Phase 3 trial by year-end 2019, same as the timeline for the lead competitor Sarepta Therapeutics Inc (NASDAQ: SRPT).

The analyst said the Phase 3 data for rivipansel in Phase 3 sickle cell anemia is likely to be the third catalyst.

Collectively, the three catalysts could lead to 3-6 percent valuation upside and possible re-rate on validation of orphan pipeline.

Price Action

Pfizer's stock traded around $42.84 per share at time of publication.

Related Links:

6 Gene Therapy M&A Targets On The Radar

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Latest Ratings for PFE

DateFirmActionFromTo
Apr 2020BarclaysMaintainsEqual-Weight
Apr 2020Morgan StanleyMaintainsEqual-Weight
Mar 2020RBC CapitalMaintainsOutperform

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!

Posted-In: Bank of America Jason Gerberry RivipanselAnalyst Color Long Ideas Price Target Analyst Ratings Trading Ideas Best of Benzinga

Latest Ratings

StockFirmActionPT
ALXNCredit SuisseMaintains147.0
CCIMorgan StanleyMaintains177.0
DLRCredit SuisseReinstates164.0
CNKMorgan StanleyMaintains18.0
CPBMorgan StanleyMaintains52.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com